Using a TPS ≥1% as the cutoff for PD-L1 positivity, E1L3N assay positivity was observed in 67.4% (31/46) of NSCLC cases, whereas 22C3 assay positivity was 73.9% (34/46). The gene discussed is CD274; the disease is non-small cell lung carcinoma.